ClinicalTrials.gg

Urinary Bladder Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,800 studies for Urinary Bladder Neoplasms across more than 10 countries. 446 are recruiting or about to start. 1,198 of them are mainly about Urinary Bladder Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Non-Muscle Invasive Bladder Neoplasms too: 1,946 studies, 518 open.

ClinicalTrials.gov finds 2,166 studies for Urinary Bladder Neoplasms. How that becomes 1,800 here

This page counts the studies the registry files under Urinary Bladder Neoplasms, and those it files under no condition that list Urinary Bladder Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,166Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −139Filed under a narrower condition, counted on its own pageNon-Muscle Invasive Bladder Neoplasms 138
  3. −52List Urinary Bladder Neoplasms as a condition, but the registry did not file them under itMost often written as “Gall Bladder Cancer” (26), “Muscle Invasive Bladder Cancer” (4), and “Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)” (3). The registry filed them under other conditions only, most often Gallbladder Neoplasms (30) and Cholangiocarcinoma (15).
  4. −236Match it another way48 name it in the title, 8 in a keyword, and 180 by a synonym or other text the search reads.
  5. 1,739Counted here and found by its search5 of them list Urinary Bladder Neoplasms in their own words; the registry filed them under no condition.
  6. +61
    Counted here, but its search does not find themThe first 20 of 61.
  7. 1,800The count on this page

Status

Completed
761
Recruiting
336
Status unknown
194
Terminated
182
Active, not recruiting
151
Not yet recruiting
96

Phase

Phase 2
547
Phase 1
371
Phase 3
171
Phase 4
29
Early Phase 1
25

Where

United States
881
China
194
France
160
Canada
154
United Kingdom
141
Spain
137

Who develops what

Add Urinary Bladder Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 42 programs from 30 companies, 21 with this as their studies’ main aim; 17 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Merck, Pfizer and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GemcitabineRecent, repeated
Evidence
  • NCT07869836 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)” · registered Oct 2026
  • NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Sep 2026
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
  • NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed88 studies
CisplatinRecent, repeated
Evidence
  • NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Sep 2026
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Cisplatin” · registered Apr 2026
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Cisplatin” · registered Aug 2025
  • NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Cisplatin” · registered Aug 2025
  • NCT06960577 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Apr 2025
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed77 studies
NivolumabRecent, repeated
Evidence
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
  • NCT06879145 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Nivolumab Injection” · registered Mar 2025
  • NCT06059547 · CatalYm GmbH · Phase 2 · background · “Nivolumab” · registered Aug 2023
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Nivolumab” · registered Feb 2022
  • NCT04180371 · BicycleTx Limited · Phase 2 · live · background · “Nivolumab” · registered Nov 2019
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)44 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Carboplatin” · registered Aug 2025
  • NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Carboplatin” · registered Aug 2025
  • NCT05911295 · Pfizer · Phase 3 · live · comparator · “carboplatin” · registered Jun 2023
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Aug 2021
  • NCT04887831 · Pharmacosmos A/S · Phase 2 · background · “Carboplatin” · registered May 2021
Eli Lilly and Company16% of its industry studies33 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Jun 2026
  • NCT07218380 · Eli Lilly and Company · Phase 3 · live · background · “Pembrolizumab” · registered Oct 2025
  • NCT06225596 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Jan 2024
  • NCT04561362 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2020
  • NCT03311334 · Sumitomo Pharma Co., Ltd. · Phase 2 · background · “Pembrolizumab” · registered Oct 2017
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)33 studies
avelumabRecent, repeated
Evidence
  • NCT06424717 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Avelumab” · registered May 2024
  • NCT06225596 · BicycleTx Limited · Phase 2 · live · comparator · “Avelumab” · registered Jan 2024
  • NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Avelumab” · registered Feb 2022
  • NCT04887831 · Pharmacosmos A/S · Phase 2 · background · “Avelumab” · registered May 2021
Pfizer44% of its industry studiesUS: Merck KGaA, Darmstadt, Germany (FDA 2017)EU: Merck KGaA, Darmstadt, Germany (EMA 2017)33 studies
DocetaxelRecent, repeated
Evidence
  • NCT07419295 · Merck & Co., Inc · Phase 3 · live · comparator · “Docetaxel” · registered Feb 2026
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Docetaxel” · registered Aug 2021
  • NCT03474107 · Astellas Pharma Inc · Phase 3 · comparator · “Docetaxel” · registered Mar 2018
  • NCT02426125 · Eli Lilly and Company · Phase 3 · background · “Docetaxel” · registered Apr 2015
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized22 studies
MitomycinRecent, repeated
Evidence
  • NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “MMC” · registered Sep 2026
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Mitomycin C” · registered Apr 2026
  • NCT04241185 · Merck & Co., Inc · Phase 3 · live · background · “Mitomycin C (MMC)” · registered Jan 2020
  • NCT04172675 · Johnson & Johnson · Phase 2 · standard-care · “Investigator Choice (Mitomycin C)” · registered Nov 2019
  • NCT01200992 · Bioniche Life Sciences Inc. · Phase 3 · comparator · “Mitomycin C” · registered Sep 2010
UroGen Pharma Ltd.70% of its industry studies22 studies
FluorouracilRecent, repeated
Evidence
  • NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “5-FU” · registered Sep 2026
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Fluorouracil” · registered Apr 2026
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “5-Fluorouracil” · registered Aug 2021
  • NCT04241185 · Merck & Co., Inc · Phase 3 · live · background · “Fluorouracil (5-FU)” · registered Jan 2020
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed22 studies
enfortumab vedotinRecent, repeated
Evidence
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2026
  • NCT06305767 · Merck & Co., Inc · Phase 2 · live · background · “Enfortumab Vedotin” · registered Mar 2024
Astellas Pharma Inc65% of its industry studiesUS: Astellas Pharma Inc (FDA 2019)EU: Astellas Pharma Inc (EMA 2022)22 studies

14 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BCG Vaccine☆ Track1 live phase-3 study: NCT06747455Chongqing Zhifei Biological Products Co., Ltd.
trastuzumab brengitecan☆ Track1 live phase-3 study: NCT07869836Sichuan Biokin Pharmaceutical Co., Ltd.
izalontamab brengitecan☆ Track1 live phase-3 study: NCT07106762Bristol-Myers Squibb
datopotamab deruxtecanApproved: US 2025 · EU 2025☆ Track1 live phase-3 study: NCT07129993Daiichi Sankyo
sacituzumab tirumotecan☆ Track2 live phase-3 studies: NCT07829783, NCT07419295Merck & Co., Inc

The 5 in phase 3 with the nearest primary completion, of 42 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Jan 2027 est.SL-28 · Second Life Therapeutics · Phase 2 named, not the main aimNCT07341737 SL-28 for Advanced Solid Tumours — primary endpoint: Number of participants with treatment-emergent adverse events · 60 enrolled
  • 23 Apr 2027 est.intismeran autogene · Merck & Co., Inc · Phase 2 main aimadded to pembrolizumabstudied with enfortumab vedotinNCT06305767 A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) — primary endpoint: Adjuvant Cohort: Disease Free Survival (DFS) · 230 enrolled
  • 30 Jul 2027 est.Anti-nectin-4 Antibody-drug Conjugate MK-3120 · Merck & Co., Inc · Phase 2 main aimNCT07222488 A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) — primary endpoint: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) · 45 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Urinary Bladder Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 34 open · Antibody-drug conjugates (ADCs) 23 open · Antimetabolites 14 open · Tyrosine kinase inhibitors (TKIs) 6 open · Antimitotic agents 6 open

Coming up

182studies finish main data collection within a year8 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger. 22 (7%) take children under 18. 3 (1%) are for women only and 7 (2%) for men only; 21 (6%) take healthy volunteers.

Recruiting studies that take each age, of 336
AgeWomenMen
1020 (6%)20 (6%)
18304 (90%)306 (91%)
30315 (94%)318 (95%)
40320 (95%)323 (96%)
50324 (96%)328 (98%)
65329 (98%)333 (99%)
75327 (97%)330 (98%)
85290 (86%)293 (87%)

Across all 1,800 studies, recruiting or not: 6% stop at 75 or younger and 1% at 65; 7% take children; 1% are for women only and 3% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urinary Bladder Neoplasms studies take

Of 194 phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 52 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 143 mo29–66 · 145 studies43 mo30–66 · 80 studies44 mo26–65 · 65 studies
Phase 1/252 mo35–78 · 67 studies45 mo32–74 · 39 studies—
Phase 252 mo36–91 · 194 studies36 mo25–52 · 39 studies58 mo39–103 · 155 studies
Phase 365 mo40–87 · 73 studies54 mo24–74 · 39 studies—
Interventional, no phase39 mo20–69 · 244 studies—40 mo21–70 · 235 studies
Observational58 mo33–… · 203 studies—60 mo30–… · 168 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered13

Show 8 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,800. Browse all 1,800 → or search them.